JAK
JAK (Janus kinase) inhibitors are compounds that target the JAK-STAT signaling pathway, which is involved in cell growth, immune response, and angiogenesis. By inhibiting JAK, these compounds can reduce the signaling that leads to the formation of new blood vessels in tumors, thereby inhibiting tumor growth. JAK inhibitors are important in the treatment of cancers and inflammatory diseases. At CymitQuimica, we offer a diverse range of high-quality JAK inhibitors to support your research in oncology, immunology, and angiogenesis.
Found 244 products of "JAK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Gandotinib
CAS:LY2784544(Gandotinib (LY2784544)) is a potent JAK2 inhibitor (IC50: 3 nM), effective in JAK2V617F(Ki: 0.245 nM).Formula:C23H25ClFN7OPurity:99.33% - 99.86%Color and Shape:SolidMolecular weight:469.94GDC-0214
CAS:GDC-0214 is an inhaled small-molecule JAK1 inhibitor and reduces fractional exhaled nitric oxide (Feno).Formula:C28H28ClF2N9O3Purity:99.75%Color and Shape:SolidMolecular weight:612.03Ref: TM-T9826
1mg93.00€5mg182.00€10mg269.00€25mg429.00€50mg610.00€100mg820.00€200mg1,099.00€1mL*10mM (DMSO)245.00€NVP-BSK805 trihydrochloride
CAS:NVP-BSK805 trihydrochloride inhibits JAK2 (0.48 nM IC50); also affects JAK1, JAK3, TYK2.Formula:C27H31Cl3F2N6OColor and Shape:SolidMolecular weight:599.93AZ960
CAS:AZ960 is an effective ATP competitive JAK2 inhibitor (IC50/Ki: <3 nM and0.45 nM).Formula:C18H16F2N6Purity:96.02% - 99.88%Color and Shape:SolidMolecular weight:354.36G5-7
CAS:G5-7 is an oral JAK2 inhibitor targeting EGFR/STAT3 phosphorylation with potential for glioma research.Formula:C22H19F2NO3Purity:97.3%Color and Shape:SolidMolecular weight:383.39Ref: TM-T8742
1mg35.00€5mg71.00€10mg96.00€25mg172.00€50mg248.00€100mg348.00€200mg470.00€1mL*10mM (DMSO)78.00€Ritlecitinib
CAS:Ritlecitinib (PF-06651600) is an orally available, selective JAK3 inhibitor and does not affect the activity of JAK1/2.Cost-effective and quality-assured.Formula:C15H19N5OPurity:98.82% - 99.92%Color and Shape:SolidMolecular weight:285.34Ref: TM-T5382
2mg37.00€5mg52.00€10mg90.00€25mg205.00€50mg290.00€100mg408.00€200mg595.00€1mL*10mM (DMSO)73.00€Decernotinib
CAS:Decernotinib (VRT-831509)(VX-509; VRT-831509) is a potent and selective Janus kinase 3 (JAK3) inhibitor with Ki of 2.5 nM; IC50 is 50-170 nM in cellular assays.Formula:C18H19F3N6OPurity:99.28% - >99.99%Color and Shape:SolidMolecular weight:392.38Ref: TM-T2636
1mg34.00€2mg48.00€5mg71.00€10mg99.00€25mg197.00€50mg295.00€100mg447.00€1mL*10mM (DMSO)79.00€(E/Z)-Zotiraciclib
CAS:(E/Z)-Zotiraciclib ((E/Z)-TG02) inhibits CDK2, JAK2, and FLT3 effectively with IC50s of 13, 73, and 56 nM, respectively.Formula:C23H24N4OPurity:97.75% - 99.92%Color and Shape:SolidMolecular weight:372.46Ref: TM-T21503
1mg43.00€2mg56.00€5mg93.00€10mg113.00€25mg200.00€50mg330.00€100mg480.00€1mL*10mM (DMSO)90.00€Momelotinib HCl
CAS:Momelotinib HCl is a JAK1/2 inhibitor, reducing anemia in myelofibrosis (MF) patients.Formula:C23H24Cl2N6O2Color and Shape:SolidMolecular weight:487.38WP1066
CAS:WP1066 is a inhibitor of JAK2 (IC50: 2.30 μM) and STAT3 (IC50: 2.43 μM) in HEL cells; shows activity to JAK2, STAT3/5, and ERK1/2, not JAK1 and JAK3.Formula:C17H14BrN3OPurity:98.92% - 99.73%Color and Shape:SolidMolecular weight:356.22AT9283
CAS:AT9283 (J-504568) is an effective multi-targeted inhibitor of JAK2(IC50=1.2 nM) and JAK3(IC50=1.1 nM), Aurora A, Aurora B and Abl(T315I).
Formula:C19H23N7O2Purity:99.83% - 99.98%Color and Shape:SolidMolecular weight:381.43AMG-47a
CAS:AMG-47a inhibits Lck, T cell growth, and degrades KRAS oncoprotein, affecting EGFP-KRASG12V but not EGFP.Formula:C29H28F3N5O2Purity:98%Color and Shape:SolidMolecular weight:535.56Pacritinib hydrochloride
CAS:Pacritinib HCl: strong JAK2/Wild-type & JAK2V617F inhibitor (IC50: 23/19 nM), used in AML & MF research.Formula:C28H32N4O3·xClHColor and Shape:SolidFLLL32
CAS:FLLL32 is an effective JAK2/STAT3 inhibitor (IC50 of <5 μM).Formula:C28H32O6Purity:97% - 97.90%Color and Shape:SolidMolecular weight:464.55Ref: TM-T6838
2mg43.00€5mg63.00€10mg88.00€25mg117.00€50mg187.00€100mg333.00€500mg797.00€1mL*10mM (DMSO)69.00€Ruxolitinib (S enantiomer)
CAS:Ruxolitinib S enantiomer (INCB18424) is the S-enantiomer of Ruxolitinib. Ruxolitinib is the first potent, selective JAK1/2 inhibitor.Formula:C17H18N6Purity:99.37% - 99.79%Color and Shape:SolidMolecular weight:306.36WHI-P97 HCl
WHI-P97 HCl is a potent and selective JAK-3 inhibitor.Formula:C16H14Br2ClN3O3Purity:99.49%Color and Shape:SolidMolecular weight:491.56Ref: TM-T4657L
2mg34.00€5mg48.00€10mg86.00€25mg138.00€50mg182.00€100mg261.00€200mg371.00€1mL*10mM (DMSO)73.00€Baricitinib phosphate
CAS:Baricitinib phosphate (INCB028050) is a selective orally bioavailable JAK1/JAK2 inhibitor.Formula:C16H20N7O6PSPurity:99.4% - 99.91%Color and Shape:SolidMolecular weight:469.41Ref: TM-T2360
5mg40.00€10mg52.00€25mg73.00€50mg93.00€100mg105.00€200mg157.00€500mg260.00€1mL*10mM (DMSO)46.00€Fedratinib
CAS:Fedratinib (TG-101348) (TG101348) is an ATP-competitive inhibitor of JAK2 (IC50: 3 nM) with significantly less potent activity against JAK3.Formula:C27H36N6O3SPurity:97.31% - 99.96%Color and Shape:SolidMolecular weight:524.68Ref: TM-T1995
1g592.00€5mg50.00€10mg65.00€50mg107.00€100mg127.00€200mg205.00€500mg447.00€1mL*10mM (DMSO)54.00€JAK3-IN-6
CAS:JAK3-IN-6 is irreversible Janus Associated Kinase 3 (JAK3) inhibitor, with an IC50 of 0.15 nMFormula:C19H18N4O3Purity:99.94% - 99.94%Color and Shape:SolidMolecular weight:350.37
